Eli Lilly and Novo Nordisk are reportedly nearing a deal with the White House to lower the prices of their popular obesity drugs in exchange for securing Medicare coverage. This move is part of a broader government effort to make expensive medications more affordable and accessible to seniors. Shares of both pharmaceutical companies rose following the news, with Eli Lilly's stock gaining 1.5% in morning trading. The proposed agreement would see the companies offer the lowest doses of their weight-loss therapies at $149 per month. Gaining Medicare coverage would significantly expand the market for these treatments to millions of Americans aged 65 and older. The announcement of the finalized deals could happen as soon as this week.